Each year, people everywhere prepare for flu season. Some will get the flu vaccine, some take vitamin supplements, some launch a vigorous handwashing campaign, while others take an entirely different approach: nuclear magnetic resonance.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, reported that patient enrollment and dosing in the Phase 2 trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan.
Tarsa Therapeutics, Inc. announced completion of its global Phase 3 ORACAL trial testing the company’s once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring.
Image analysis is critical to understanding the results of large-scale cell-based screening assays used in drug discovery. High-content screening methods present challenges for extracting, analyzing, integrating, and sharing assay results.
The FlowCAM Front-Fill Illumination particle imaging and analysis system from Fluid Imaging Technologies is the first to feature bidirectional front and back lighting, which illuminates the surfaces of opaque particles and reveals their true colors and textures.
Malvern Instruments has launched the Zetasizer µV with OmniFACE and OmniSEC, a SEC-LS (size exclusion chromatography - light scattering) detector package dedicated to protein analysis.
Vanda Pharmaceuticals Inc. said it turned a profit in the fourth quarter on reduced expenses, including lower costs related to its schizophrenia drug Fanapt.
Momenta Pharmaceuticals Inc. said it turned a fourth-quarter profit and achieved profitability for the first time in 2010 as a generic version of the anti-clotting drug Lovenox pushed revenue growth.
Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy. The findings suggest that preladenant may offer a new supplemental treatment with fewer complications.
Scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes.
BioInvent International AB and co-development partner ThromboGenics NV have announced positive results of a TB-402 Phase 2 trial, evaluating the product’s efficacy and safety for the prevention of venous thromboembolism after orthopaedic surgery.
Renovo Group plc, which develops drugs to reduce scarring, improve wound healing, and enhance tissue regeneration, announces that its first EU Phase 3 trial for Juvista in scar revision surgery (REVISE) did not meet its primary or secondary endpoints.
Irish drug developer Shire Plc. said its fourth-quarter profit fell on higher costs, but the results met Wall Street expectations. The company earned $165.1 million, down from $174.3 million.
Eli Lilly and Co. named company insider Sue Mahony as president of its cancer drug business. The change is effective immediately. Mahony has worked at Eli Lilly for about 10 years, the company said.
In order to ensure smooth operation during bioanalytical studies, a novel model, where a principal investigator with direct control over the entire study is the core of the project, has been developed.